© Eximore.co.il

Office: High-Tech Village, Givat Ram,

P.O Box 39158, Jerusalem 91391

Tel: +972-(0)54-2342644

The Team

CEO, Co-Founder & Director
Ishay Attar

Entrepreneur and leader of medical devices / biotech companies. 17 years of experience as CEO, VP Business Development and Product Manager. Founder of LifeBond and NeuroQuest. Led multiple successful rounds of financing summing up to tens of millions of dollars cash investment.

Serving as VP for Business Development at Xenia Venture Capital and VLX Ventures. Prior to Xenia, Daphne was VP BizDev at Medingo that was acquired by Roche. Recently, Daphne founded Tarsius Pharma, developing an innovative treatment for uveitis, the 3rd leading cause for blindness. She is also a lecturer at the Interdisciplinary Center (IDC) Herzliya and director of several start-up companies.

Board Chair
Dr. Daphne Haim-Langford
Chief Technology Officer
Eyal Sheetrit
Entrepreneur of medical devices / biotech companies. Experience as technology advisor, business consultant and product management. Prior to joining Eximore, was the product manager at Ethicon Biosurgery unit of J&J. and has experience as a strategic consultant. Vast experience with hands on development of products in the field of complex biomaterials.  Holds a BSc. and MSc. degree in Biotechnology Engineering from the Technion University and an MBA from Tel Aviv  University.
Director & Clinical
Dr. Yafit Stark

As VP in Teva Pharmaceutical Industries, Ltd. Chief Clinical Officer Innovative R&D, she established the global innovative clinical trial infrastructure and strategy, and managed the global clinical research division. Amongst other achievements, Dr. Stark was responsible for the clinical development of Teva’s ethical products.

A senior ophthalmologist and surgeon at the Assaf Harofe Medical Center Department of Ophthalmology, and a Senior Clinical Lecturer at the Tel Aviv University Faculty of Medicine. Expert in Glaucoma and chairman of the Israeli Glaucoma committee.

CMO
Dr. Yaniv Barkana
Strategic Advisor/Business Development
Marc D. Kirshbaum, JD
Former COO, Allegro Ophthalmics, leading $40 million funding efforts, increasing the company’s valuation from $5 million to $150 million and less than 25% dilution. Prior to joining Allegro, was the President & COO of Private Access, leading several key milestones for the company, including a $6 million strategic investment and partnership with Pfizer. Currently serving on the board of multiple technology companies and advising investors and CEOs/founders on strategy, leadership & execution.